Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v4-FR
Language French French
Date Updated 2024-03-11 2024-03-11
Drug Identification Number 02329271 02329271
Brand name OCTREOSCAN OCTREOSCAN
Common or Proper name Kit for the preparation of Indium In 111 Pentetreotide Kit for the preparation of Indium In 111 Pentetreotide
Company Name CURIUM CANADA INC CURIUM CANADA INC
Ingredients PENTETREOTIDE INDIUM IN 111 CHLORIDE PENTETREOTIDE INDIUM IN 111 CHLORIDE
Strength(s) 10MCG 111MBq 10MCG 111MBq
Dosage form(s) POWDER FOR SOLUTION KIT SOLUTION POWDER FOR SOLUTION KIT SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 10ml 10ml
ATC code V09IB V09IB
ATC description
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2024-03-03 2024-03-03
Estimated end date 2024-03-10 2024-03-10
Actual end date 2024-03-10 2024-03-10
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments The most recent lot of Octreoscan did not meet quality specifications for release. As a result, product will not be available for shipment Sunday, Mar 3 and Monday, Mar 4. The next lot is scheduled to release Sunday, Mar 10. We apologize for any inconvenience caused by this issue. The most recent lot of Octreoscan did not meet quality specifications for release. As a result, product will not be available for shipment Sunday, Mar 3 and Monday, Mar 4. The next lot is scheduled to release Sunday, Mar 10. We apologize for any inconvenience caused by this issue.
Health Canada comments